



Huons Dexcom G6

개인별 맞춤형 연속혈당측정시스템(G6)을 이용한 당뇨병 환자의 자가 관리에 필요한 센서와 함께 의료 현장에서 측정된 포도당 농도를 연속적으로 측정하여 포도당 농도를 모니터링하는 장치로 자가감시용으로 집에서 사용하거나 의료기관 내 당뇨병 환자의 포도당 농도 측정 및 관리에 사용된다.

*이 제품은 의료기기이며, 사용상의 주의사항과 사용방법을 잘 읽고 사용하십시오.

광고문의처 : 고객센터 12021-0001(주휴기간 24.07.28)



HOME > PHARMA

LegoChem licenses in ADC drug candidate from Italy

Lee Han-soo | Published 2021.05.03 14:59



LegoChem Biosciences said Monday that it has licensed an anti-Trop2 (tumor-associated calcium signal transducer) antibody from Mediterranean Theranostic Srl, an Italian biopharmaceutical firm.

The total contract size, including advance payments and milestones paid according to the development stage, is \$47.75 million. LegoChem has secured the worldwide rights of the anti-Trop2 antibody for antibody-drug conjugate (ADC) use through this contract.



LegoChem Biosciences has licensed in an ADC candidate substance from Mediterranean Theranostic Srl, an Italian biotech company. (LegoChem)


"The company has verified the advantages of both drug efficacy and toxicity for the licensed in antibody technology, as it selectively binds only to Trop2 antigens expressed in cancer cells and does not bind to the same antigens present in normal cells," the company said. "We have derived clinical candidates that apply Legochem's ADC technology to the antibody through joint research over two years."

Through comparative tests in various cancer types, the company has verified the drug's superior efficacy and safety compared to Immunomedics' Trodelvy and Daichi Sankyo's DS-1062 and has confirmed the possibility of

Recent News

- President calls for shifting to 'Omicron response s...
- FDA gives priority to biologics over JAK inhibitors...
- Will Nerlynx satisfy unmet demand for early brea...
- Noul seeks to list shares on Kosdaq market in Ma...
- Biopharma stocks lost ₩30 trillion amid series of ...

Photo News



Most Viewed

- Korea approves Novavax's Covid-19 
- Sanofi's Dupixent targets chronic 
- Korean consortium to make Russia's Covid-19 
- [CES 2022]Health technologies prompted 
- [CES 2022] 'Women's health risk from 
- Samsung Biologics seeks new growth 
- Myongji Hospital 



The recent acquisition of Mediterranean Theranostic's anti-Trop2 antibody is part of LegoChem's VISION 2030 strategy announced last year.

The company vowed to make a strategic shift toward increasing the value of technology transfer through independent development from the initial technology transfer center to the clinical stage to become the world's best ADC company.

"We expect that the Trop-2 ADC development candidate secured through this contract will be one of the first candidates for this strategy," the company said.

Legochem Bio President Kim Yong-zu also said, "To become a global clinical-stage company, we are aggressively trying to expand our clinical pipeline."

As part of this goal, the company is conducting joint research and development with several local and foreign antibody companies to secure new pipelines, he added.

트윗



Lee Han-soo corea022@docdocdoc.co.kr

[See Other Articles](#)

Copyright © KBR Unauthorized reproduction, redistribution prohibited

Contents for you

by

FDA approves JAK inhibitors as 2nd-line...

KRX decides to delist Sillajen from Kosdaq

Reach your potential clients with Native ads!

FDA clears LG Chem for phase 1 trial of type-2...

President calls for shifting to 'Omicron response system'

Big Pharma swept new drug approvals in Korea I...



News That You Haven't Seen

Korea approves Novavax's Covid-19 vaccine

Sanofi's Dupixent targets chronic pruritus

Korean consortium to make Russia's Covid-19 vaccine breaking down



Comments 0

 Available after login.

If you post infringement of rights, abusive language, or content that derogates a specific object, it may be subject to the terms of use and related laws. Log out after use on public devices.

0 / 400

Important News




President calls for shifting to 'Omicron response system'



FDA gives priority to biologics over JAK inhibitors



Will Nerlynx satisfy unmet demand for early breast



Noul seeks to list shares on Kosdaq market in March



Biopharma stocks lost ₩30 trillion amid series of bad



FDA clears LG Chem for phase 1 trial of type-2

Important

Noul seeks to list shares on Kosdaq market in ...

Latest

St. Mary's Hospital develops AI-based...



About KBR

Tip off

Advertising

Site Feedback

Privacy Policy

Adolescent Protection Policy

E-mail address privacy

Korea Biomedical Review

The Korean Doctors' Weekly Co., Ltd 76-1, Dongmak-ro, Mapo-gu, Seoul, Korea Tel : 82-2-2646-0852 Fax : 82-2-703-3916

Title : KBR Online newspaper registration number : Seoul 아 04285 Date of registration : December 19, 2016 Publishing date : February 22, 2017

Publisher-Editor : Yang Kyung-cheol Executive Editor : Choi Sung-jin Chief Executive Officer : Yang Kyung-cheol

Copyright © KBR. All rights reserved.

POWERED BY 

